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Prostate tumor attenuation in the 
nu/nu murine model due to anti-
sarcosine antibodies in folate-
targeted liposomes
Zbynek Heger1,2, Hana Polanska1,3, Miguel Angel Merlos Rodrigo1,2, Roman Guran1,2, 
Pavel Kulich4, Pavel Kopel1,2, Michal Masarik1,3, Tomas Eckschlager5, Marie Stiborova6, 
Rene Kizek1,2 & Vojtech Adam1,2
Herein, we describe the preparation of liposomes with folate-targeting properties for the 
encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive 
inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome 
internalization. We examined the effects of repeated administration on mice PC-3 xenografts. Sar@LIP  
treatment significantly increased tumor volume and weight compared to controls treated with empty 
liposomes. Moreover, antisarAbs@LIP administration exhibited a mild antitumor effect. We also 
identified differences in gene expression patterns post-treatment. Furthermore, Sar@LIP treatment 
resulted in decreased amounts of tumor zinc ions and total metallothioneins. Examination of the spatial 
distribution across the tumor sections revealed a sarcosine-related decline of the MT1X isoform within 
the marginal regions but an elevation after antisarAbs@LIP administration. Our exploratory results 
demonstrate the importance of sarcosine as an oncometabolite in PCa. Moreover, we have shown that 
sarcosine can be a potential target for anticancer strategies in management of PCa.
Prostate cancer (PCa) was the most common cause of cancer in men in the USA in 2013, afflicting one in nine 
men over the age of 651. Distinct sets of genes, proteins, and metabolites orchestrate cancer progression from 
a precursor lesion to localized disease and finally to metastatic cancer2. However, despite a broad knowledge 
of gene/protein expression profiles in PCa, complex metabolomic alterations are still not yet understood. 
PCa-specific metabolites can be effective targets that are exploitable in not only early diagnostics but also in the 
enhancement of therapeutic possibilities.
In 2009, Sreekumar and coworkers discovered that the urinary level of sarcosine (N-methylglycine), an inter-
mediate by-product of glycine synthesis and degradation, increased within the localized PCa and metastatic 
PCa cohorts3. Although the linkage of sarcosine with PCa development4–6 and its potential in the diagnosis of 
early-stage tumors have been reported7, its use as a biomarker is still unclear8. Khan et al. demonstrated that 
addition of sarcosine induced invasion and intravasation in an in vivo PCa model9. Their comprehensive study 
of sarcosine-related enzymes shed light on sarcosine as a substantial PCa oncometabolite that can impact the 
oncogenic potential of prostate cells. Similarly, our in vitro pilot study revealed that sarcosine supplementation 
affects the redox status of PC-3 cells10. Hence, we used our anti-sarcosine antibodies (antisarAbs), whose immu-
noperformance was tested in ref. 11, as cargo for liposomal nanotransporters (antisarAbs@LIP) to promote the 
internalization of these antibodies into intracellular regions and the subsequent neutralization of sarcosine. To 
increase the liposomal shuttling efficiency, the outer surface was modified with folic acid (FA)12. This Trojan horse 
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process performed through FA-folate receptor affinity promotes cellular uptake via clathrin-mediated endocyto-
sis, which enables the passage of larger objects (including liposomes) across cellular membranes13.
The main objective of our study was to determine whether the administration of antisarAbs and sarcosine 
liposomal formulations affected PC-3 xenografts in terms of tumor growth and gene expression patterns to obtain 
insight into the uncertain role of sarcosine in PCa development. To enhance the uptake into prostate tumor tissue, 
we utilized FA-targeted liposomes, which enabled us to investigate sarcosine-related cellular issues in highly spe-
cific way. A special emphasis was placed on the administration effects on a key regulatory factor in the inter-
mediary metabolism of prostate cells (zinc) and a substantial transporter protein involved in zinc homeostasis 
(metallothioneins, MTs).
Results
Characterization and in vitro intracellular uptake of 1,2-dioleoyl-sn-glycero-3-phosphoethan-
olamine (DOPE) liposomes. Liposomal sarcosine and antisarAbs were produced using the lipidic thin-film 
hydration method14 as well as control liposomes without cargo (hereinafter denoted as No cargo). Subsequent 
surface modification with FA was achieved through an esterification reaction using the zero-length linker 
1,1′ -carbonyldiimidazole (CDI). Table 1 demonstrates the relatively high yields of encapsulation for both types of 
cargos [loading efficiency (LE) 78.9% for sarcosine, LE 56.2% for antisarAbs].
Transmission electron microscopy (TEM) observations revealed spherical multilamellar vesicles (Fig. 1A) 
averaging 172 nm in diameter (Fig. 1B). FA-modified liposomes exhibited ζ potential ≈ + 22 mV. Successful sur-
face modification was confirmed using optical methods (Fig. 1C). The absorption spectra of antisarAbs@LIP 
revealed two absorption maxima, one due to the presence of encapsulated antibodies (λ = 280 nm) and one due 
to FA (λ = 365 nm). Liposome suspensions exhibited the characteristic fluorescence emission peaks of FA (insert 
in Fig. 1C), suggesting successful coating of FA molecules onto the liposome surfaces.




Table 1.  Loading efficiencies (LE%) of sarcosine and antisarAbs in folate-targeted liposomes. Values are 
expressed as the mean of three independent replicates (n = 3).
Figure 1. Characterization of FA-modified liposomal formulations of sarcosine and antisarAbs.  
(A) TEM micrograph (length of scale bar is 50 nm) and (B) dynamic light scattering analyzed in PBS, pH 7.4, 
with corresponding ζ potential inserted. (C) UV-Vis absorption spectrum of antisarAbs-bearing liposomes 
(λ = 270 nm corresponds to encapsulated antisarAbs, and λ = 365 nm corresponds to surface modification 
with FA) with the inserted photoluminescence spectra of liposomes before and after modification with FA 
(λ exc = 360 nm). (D) Time dependence of the cellular uptake of QD-labeled antisarAbs@LIP into PC-3 cells 
obtained via inverted fluorescence microscopy (length of scale bar is 200 μ m). Cells were incubated with 10 μ M 
QD-labeled antisarAbs@LIP. (E) Competitive inhibitory effects in PC-3 cells. Values represent the mean ± SD of 
three experiments. Asterisks indicate significant differences (p < 0.05).
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In vitro cellular uptake experiments were performed using human prostate cancer PC-3 cells, which overex-
press folate receptors15,16. The uptake of quantum dots (QD)-labeled antisarAbs@LIP was evaluated over time 
(0–12 h) and is shown in Fig. 1D. After 6 h of incubation, the fluorescence considerably increased, and high 
uptake was also measured after 12 h of incubation, demonstrating that liposomes interacted with PC-3 cells. The 
uptake of substances into cells via folate receptors is reduced in the presence of excess amounts of FA due to com-
petitive inhibitory effects. Hence, to ascertain that liposomes were indeed internalized through folate targeting, 
we assessed the cellular uptake of QD-labeled antisarAbs@LIP in the presence of FA, and the results from this 
assay are illustrated in Fig. 1E. The cellular uptake of QD-labeled antisarAbs@LIP was significantly reduced in 
PC-3 cells as the FA concentration increased. Thus, our results indicate the important role of folate receptors in 
the cellular uptake of our liposomal formulations in PC-3 cancer cells.
In vivo effects of antisarAbs@LIP and sar@LIP on PC-3 xenografts. Treatment of mice PC-3 xeno-
grafts with various formulations of liposomes began when the tumor volume reached approximately 30 mm3 and 
was considered the first treatment day. The mice in all experimental groups were administered treatments nine 
times by intraperitoneal injection for 35 days. The tumor growth time profile obtained by measuring the tumor 
diameter in the test animals twice per week is presented in Fig. 2A. Treatment with sar@LIP remarkably enhanced 
tumor growth from approximately the 7th day of administration. In contrast, antisarAbs@LIP administration 
showed moderate antitumor activity. Tumor weight was calculated to evaluate the impact on tumors and is shown 
in Fig. 2B. Administration of antisarAbs@LIP led to the inhibition of tumor weight by 32.5%. Notably, the mean 
weight of the excised tumors was approximately 71.4% higher in mice treated with sar@LIP than in mice treated 
with empty liposomes (No cargo). No mice died or had to be euthanized before the endpoint of the experiment, 
and administration did not cause significant differences in mouse weight.
Gene expression patterns and apoptosis in excised tumors. To understand the gene expression pat-
terns, we performed electrochemical microarray analyses of RNA isolated from tumor tissues. We compared 
the effects of both administration types with the expression patterns of PC-3 xenografts treated with empty 
liposomes (complete array heatmaps are depicted in Supplementary Figure 1, together with a control expres-
sion heatmap of benign prostate PNT1A cells). The Venn diagram in Fig. 3A illustrates that the administration 
of sar@LIP and antisarAbs@LIP resulted in significant differential expression patterns, with only 17 overlap-
ping genes up-regulated as a result of treatment with either sar@LIP or antisarAbs@LIP. The other (n = 121 and 
n = 118, respectively) up-regulated genes were uniquely connected to individual treatments. The complete lists 
of up- and down-regulated genes and their relative expression levels are shown in Supplementary Tables 2 and 3. 
Furthermore, we highlighted 12 genes that were specific to any aspect of PCa (Fig. 3B). Most (n = 10) were signifi-
cantly up-regulated by the presence of exogenously added liposomal sarcosine (p < 0.05). In contrast, antisarAbs@
LIP administration led to the up-regulation of only two of these genes (KLK3 [kallikrein 3] and pro-apoptotic 
BAX [Bcl2-associated X protein) and, moreover, caused significant down-regulation of GAB2 (growth factor 
receptor-bound protein 2 (GRB2)-associated binding protein 2). The annotation analysis from GoMiner indicated 
that some of those genes, including CCND1 (cyclin D1, alpha polypeptide), BAX, TEGT (transmembrane BAX 
inhibitor motif containing 6), E2F3 (E2F transcription factor 3) or PDGFRB (platelet-derived growth factor receptor, 
beta polypeptide), were related to the positive regulation of cell proliferation and apoptosis. Noteworthy, sar@LIP 
induced the up-regulation of SLC43A1 (solute carrier family 43, member 1), whose major role is amino acid trans-
port and the supply of nutrients into cancer cells. We further detected the apoptosis-related proteins in excised 
xenografts. Figure 3C demonstrates that antisarAbs@LIP treatment slightly increased the amount of cleaved 
caspase-3 when compared to sar@LIP administration, which is in agreement with the expression of pro-apoptotic 
BAX.
Figure 2. In vivo antitumor efficacy of liposomal formulations in PC-3 tumor xenografts. (A) Average 
tumor volume in nude mice bearing subcutaneous PC-3 tumors. Arrows indicate the time of therapeutic 
injections (i.p.). (B) Average tumor weight at the endpoint of the experiment. Inserted are chosen photographs 
of PC-3 tumors after termination. Values are expressed as the mean of five independent replicates (n = 5). 
Vertical bars indicate standard error. Asterisks indicate significant differences (p < 0.05) compared to the group 
treated with empty liposomes.
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Zinc and MT content in tumor tissue. Zinc homeostasis maintains physiological conditions in PCa, and 
zinc levels are significantly diminished in cancerous tissue (Fig. 4A). Thus, we determined the zinc levels in excised 
tumors. Figure 4B illustrates that sar@LIP administration significantly decreased the amount of zinc in tumor 
tissue (mean of 14.3 μ g/g compared to 23.2 μ g/g in mice treated with empty liposomes). In contrast, treatment 
with antisarAbs@LIP did not alter zinc levels in tumor tissue. Zn regulation is partially performed through MT 
proteins. Thus, we focused on the expression profiles of mRNAs encoding three isoforms of MT (1B, 1X and M). 
Figure 4C indicates that only antisarAbs@LIP administration significantly up-regulated MT1X and MTM mRNA 
expression levels (p < 0.05). To further elucidate the disparities in MT levels in tumor tissue after the treatments, 
we performed electrochemical examination by differential pulse voltammetry utilizing Brdicka’s solution as an 
electrolyte. Because the MTs exhibit exceptional thermal stability, tumor homogenates were denatured and fil-
tered to remove undesired interfering particles. Figure 4D demonstrates that voltammetry partially supported the 
results obtained using microarray and that antisarAbs@LIP administration elevated the MT content to 35.3 μ g/g 
compared to mice treated with empty liposomes (mean 30.3 μ g/g). In contrast, sar@LIP treatment significantly 
decreased MT content in xenograft tumors (mean 13.6 μ g/g). Overall, our results indicate a plausible linkage 
between sarcosine metabolism and metal homeostasis in PCa.
Examination of tumor cross-sections. We further visualized molecules using imaging mass spectrom-
etry (IMS). Figure 5 shows the images that were first obtained by performing matrix-assisted laser/desorption 
ionization (MALDI)-IMS and a hematoxylin and eosin (H&E) staining of the tumor section. The tumor speci-
mens stained by H&E were ascertained by microscopic examination, which revealed no observable histological 
changes in the control and post-treatment excised tumor xenografts (Fig. 5A–C). Figure 5Aa–Cd depicts typical 
images that were obtained from MALDI-IMS and were used to visualize the distribution of predominant peaks 
(m/z 4484 Da, m/z 7207 Da and m/z 14739 Da) determined in the mean mass spectra represented in Fig. 5Ae–Ce. 
Generally, our treatment protocol did not result in expression pattern changes. However, our treatment protocol did 
affect the intensities of chosen peaks. The highest differences were found in the case of m/z 7207 Da after sar@LIP 
administration, with a substantially reduced ion signal compared to empty liposomes and antisarAbs@LIP. The spa-
tial distribution was relatively homogenous, except for the margins of tumors treated with sar@LIP, where the ion 
signal was nearly lost. AntisarAbs@LIP treatment resulted in elevated signal at the margins. Subsequent on-tissue 
digestion resulted in the successful identification of three predominant peaks as follows: m/z 4 484 Da corresponded 
Figure 3. Effects of administration on the gene expression patterns. (A) Venn diagram showing the 
overlapping genes that were up-regulated after both types of administration. (B) Representation of the relative 
expression levels of genes specific to any aspect of PC, which were significantly up- or down-regulated in post-
treatment tumor tissues. GAB2 – Growth factor receptor-bound protein 2 (GRB2)-associated binding protein 
2; SLC43A1 – Solute carrier family 43, member 1; KLK3 – Kallikrein 3 (prostate-specific antigen) PSA; KLK4 – 
Kallikrein 4 (prostase, enamel matrix, prostate); CCND1 – Cyclin D1, alpha polypeptide; TCF7 – Transcription 
factor 7 (T-cell specific, HMG-box); PART1 – Prostate androgen regulated transcript 1; PSCA – Prostate stem cell 
antigen; E2F3 – E2F transcription factor 3; PDGFRB – Platelet-derived growth factor receptor, beta polypeptide; 
BAX – Bcl2-associated X protein, TEGT – Transmembrane BAX inhibitor motif containing 6. Values are expressed 
as the mean of three independent replicates (n = 3). Vertical bars indicate standard error. Asterisks indicate 
significant differences (p < 0.05) compared to the group treated with empty liposomes. (C) Western blot analysis 
for the xenografts expression of caspase-3 and cleaved caspase-3.
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to beta-defensin 1 (DEFB1, approx. MASCOT score 65.2), m/z 7 207 Da corresponded to MT isoform 1X (MT1X 
approx. score 55.0), and m/z 14 739 Da corresponded to cytochrome b5 (CYB5, approx. score 78.1).
Discussion
In this study, we demonstrated that FA-modified liposomes are suitable to target cancer cells, as folate receptors 
are overexpressed in a wide variety of tumors, including PCa17. We provide evidence that sarcosine plays a sub-
stantial role in PCa progression and can be a potential target for the development of novel treatment modalities.
PCa remains a leading cause of illness and death among men in the US and Western Europe. Autopsy series 
have revealed small prostatic carcinomas in up to 29% of men age 30 to 40 years and 64% of men age 60 to 70 
years. Moreover, the risk of PCa is 1 in 6, and the risk of death due to metastatic PCa is 1 in 3018. Despite these 
astounding statistics, the mechanism of prostate tumorigenesis is still not well understood, although it appears 
to be multifactorial.
Thus, the rationale of encapsulating sarcosine and antisarAbs is primarily to further understand the role of 
sarcosine as a suspicious oncometabolite important in PCa development. We used a liposomal transporter due to 
the inability of antibodies to enter the intracellular space, which can occur through the well-described FA-folate 
receptor interaction19–21, leading to folate receptor-mediated endocytosis. The encapsulation into the FA-modified 
liposomes produced stable delivery systems, which enabled highly specific investigation of sarcosine-induced 
cellular events. We anticipate that exploitation of advanced nanomaterials for research on cancer metabolism 
can benefit from their exceptional properties, including specificity, prolonged circulation and wide payload spec-
trum of studied substance. Indeed, our results confirmed interactions between PC-3 cells and our designated 
nanotransporter in vitro. These were first provided by electrostatics between the negatively charged proteogly-
cans contained on cellular surfaces and the positively charged liposome surface. Second, folate targeting facili-
tated the endocytosis of liposomes, as was proved by our competitive inhibitory assay (Fig. 1E). Considering the 
in vivo tumor microenvironment, the enhanced permeability and retention effects should be taken into account 
as important mediators of the increased liposome accumulation in the tumor mass22.
As approximations of human disease, animal models of cancer are critical for the understanding of the piv-
otal mechanisms of cellular transformation and the development of novel antitumor therapies. Therefore, it is 
Figure 4. Effect on treatment on tumor zinc and metallothionein content. (A) Schematic depiction of zinc 
and metallothioneins and their importance in benign and malignant prostate cells. In malignant cells, ZIP 
transporters are inhibited through the Ras-Raf-Mek-Erk cascade, resulting in a decrease of Zn2+ ions in the 
cytosol. This phenomenon, together with Bcl-2 activity, inhibits the pro-apoptotic activity of cytochrome 1 
c (CytC) in these cells. MT expression is closely linked to the Zn amount in the intracellular space. (B) Zinc 
levels in PC- 3 tumors after administration of liposomal sarcosine and antisarAbs. (C) Relative expression 
levels of mRNAs encoding different human metallothionein isoforms (1B, 1X and 1M) in tumor tissue after 
administration of liposomal sarcosine and antisarAbs, analyzed using electrochemical microarray. (D) 
Determination of total MTs using the Brdicka reaction after sample denaturation. Values are expressed as the 
mean of three independent replicates (n = 3). Vertical bars indicate standard error. Asterisks indicate significant 
differences (p < 0.05) compared to the group treated with empty liposomes.
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important to have systems that can mimic the tumor biology observed in patients, providing accurate informa-
tion on the signaling networks and biochemical pathways in the tumor microenvironment23. The direct addition 
of sarcosine imparted an invasive phenotype to benign prostate cells, and the number of motile prostate cells was 
significantly higher upon sarcosine treatment3. Therefore, in this work, PC-3 cells were grown as xenografts in 
nude mice as a model for sar@LIP and antisarAbs@LIP administration. We found that sar@LIP exerted a dra-
matic tumor growth-supporting activity, leading to increases in tumor volume and weight. In contrast, antisar-
Abs@LIP exerted mild antitumor activity, as shown in Fig. 2A,B.
We acknowledge that these findings are in agreement with results published by Khan and coworkers, who 
reported the substantial role of sarcosine in invasion and intravasation in an in vivo PCa model9. We believe 
that these findings portray the importance of sarcosine in PCa progression. Furthermore, we expanded this 
knowledge to include the possible exploitation of anti-sarcosine antibodies, which caused mild antitumor effects. 
However, further examination must be performed to distinguish and overcome possible drawbacks, such as their 
low tissue penetration24.
Sarcosine is produced from glycine by the enzymatic action of glycine-N-methyltransferase (GNMT), which 
is frequently elevated in localized and metastatic PCa relative to benign tissue25. However, how the elevated sar-
cosine levels affect the cellular microenvironment is uncertain. As a first level of organization, we examined the 
administration-related gene expression patterns of tumors using microarrays, which provided a snapshot of the 
cell functions and processes of thousands of genes and should yield insights concerning changes in gene expres-
sion associated with tumor cellular dysfunction and any concomitant regulatory pathways. Gene microarrays 
revealed the interesting differential expression profiles of a number of cancer-related genes in post-administration 
analyses. In particular, the c-JUN and c-FOS proto-oncogenes, MMP2, an independent predictor of decreased 
PCa survival rates, and CCDN1, a cell cycle progression regulator26–28, were up-regulated only after sar@LIP 
treatment, illustrating that sarcosine can markedly affect the cellular microenvironment of PCa cells. Within 
the significantly regulated genes, we further selected those that are associated with any aspect of PCa (Fig. 3B). 
Noteworthy, GAB2, which encodes the GAB2 scaffolding protein, which serves as a platform for the assembly 
of signaling systems fundamental for PCa development29, was significantly down-regulated by antisarAbs@LIP 
(p < 0.05). This prevents PCa cells from interactions with signaling molecules, which are vital for tumorigenesis30. 
On the contrary, sar@LIP treatment induced slight up-regulation of GAB2, which supports its tumor stimula-
tory role. These findings describe a plausible mechanism for the moderate antitumor activity of antisarAbs@LIP, 
together with the capability to up-regulate BAX, encoding Bcl-2-like protein 4, which accelerates programmed 
cell death through increase of the opening of the mitochondrial voltage-dependent anion channels, which leads 
to the loss in membrane potential and the release of cytochrome c (Fig. 4A)31. In contrast, sar@LIP induced the 
up-regulation of a broad spectrum of genes related to the positive induction of cell proliferation (CCND1, E2F3, 
PDGFRB and TEGT, a described BAX inhibitor), which corresponds to the tumor growth enhancement observed 
in vivo after sar@LIP administration. Interestingly, both types of treatments triggered up-regulation of KLK3, 
Figure 5. Administration results in disparities in a spatial distribution of proteins. H&E-stained cross 
sections of PC-3 xenografts (A) without treatment and after treatment with (B) liposomal antisarAbs and 
(C) liposomal sarcosine. Tumor sections (scale bar = 100 μ m) were (a) scanned and utilized for MALDI-IMS 
profiling. Normalized pseudo-colored images of the spatial distribution of proteins with m/z values of:  
(b) 4484 ± 0.25% Da, (c) 7207 ± 0.25% Da and (d) 14379 ± 0.25% Da. (e) Mean mass spectrum of spectra 
obtained from MALDI IMS of PC-3 tumors. DHB was used as a matrix. The conditions used to acquire the 
MALDI spectra were as follows: 1,600 shots per raster spot, 65% laser energy and spatial resolution of 100 μ m. 
All treated animals were euthanized 35 days after dosing. The scale bar length for the MALDI-IMS scans  
is 2 mm.
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which encodes prostate-specific antigen (PSA) - a serine protease produced by epithelial cells in prostate, which 
represents the gold standard biomarker of PCa32. We hypothesize that this phenomenon is due to utilization of FA 
for liposomes surface modification. Tisman and Garcia have demonstrated that FA supplementation is associated 
with a serum PSA acceleration, while its withdrawal from diet resulted in a significant PSA decline33. Despite that 
there is a lack of information describing a stimulation of PSA through FA exploited for folate targeting. Hence, 
further research is needed to rule out this phenomenon. Proliferative stimuli are highly dependent on metabolic 
responses. A critical aspect of the re-programming of cancer cell metabolism involves changes in the glycolytic 
pathway, referred to as the Warburg effect. Glutaminase is a key enzyme involved in the Warburg effect, and its 
role is to convert glutamine, an amino acid essential for tumor growth, to glutamate34. In sar@LIP, but not in 
antisarAbs@LIP-administered tumors, we found significantly up-regulated expression of GLS, which encodes 
glutaminase. Furthermore, PCa cells overexpress L-type amino acid transporters (LATs) to enhance their nutrient 
status and to stimulate cell growth35. Our results also illustrate that sar@LIP administration results in significant 
up-regulation of SLC43A1, which encodes LAT3 proteins. LAT3 can contribute to various signaling pathways, 
including mammalian target of rapamycin complex 1, implicated in tumorigenesis36. Our pioneering data high-
light the important role of sarcosine in PCa cells. However, the mechanism of action by which sarcosine affects 
these genes needs to be further investigated.
In normal prostate tissue, Zn2+ ions enter cells via ZIP (Zrt- and Irt-like protein) transporters. Crossing the 
membranes, zinc induces BAX to form pores in the outer mitochondrial membrane, through which cytochrome 
c (CytC) is released into the cytosol. CytC then interacts with caspases to cause apoptosis (Fig. 4A). The growth 
effect of low intracellular zinc levels results from the elimination of the pro-apoptotic effects of zinc. Together 
with increased energy production, the growth effect promotes transformation into energy-efficient, proliferative, 
malignant cells. Our data suggest that sar@LIP administration is significantly associated with decreased amounts 
of zinc in tumor tissue (p < 0.05). We anticipate that the disruption of the tight homeostatic control of the cellular 
zinc level serves as an indicator of the stimulant effects of sarcosine on PCa cells. AntisarAbs@LIP treatment 
resulted in the partial regression of zinc homeostasis. Thus, sarcosine accumulation and zinc depletion appear to 
play important roles in PCa development.
MTs are intracellular proteins that bind transition metals, including zinc. Hasumi et al. demonstrated that 
similarly to zinc, decreased levels of MT are associated with PCa37. Furthermore, zinc treatment up-regulates 
MT expression. Notably, after antisarAbs@LIP administration, similar effects were achieved on both the mRNA 
(isoforms 1B; 1X and 1M) and protein levels (total MTs). In contrast, sar@LIP significantly decreased the amount 
of total MT protein but not the transcribed mRNA. These results correspond to our preliminary in vitro study 
with PC-3 cells administered sarcosine10. The amount of MT was reduced in sarcosine-supplemented cells in 
a time-dependent manner. Alterations in zinc-metallothionein metabolism are described as the early signs 
of PCa progression38, and our data reveal that sarcosine decreases their amounts in tumor tissue. MT expres-
sion is tightly regulated by the intracellular zinc pool through metal-regulatory transcription factor 1. Thus, 
MT down-regulation is likely linked to decreased zinc, which reflects the proliferative and malignant transfor-
mation of the prostate cells. Such a phenomenon should also be reflected in a significant down-regulation of 
MT-encoding mRNA. Nevertheless, it is important to note that we examined only the three basic isoforms of 
MT1, and many other distinct isoforms have been identified39. Moreover, the correlation between transcrip-
tion and translation is affected by a number of factors, including expression rates and protein stability40. Thus, 
single-cell analysis with RNA probes and antibodies should be performed to provide detailed insight.
Previously, it was shown that zinc biodistribution is not uniform, even in the same anatomical region 
of the prostate. Leitao and coworkers identified significant differences among transitional and peripheral 
zones41. However, to the best of our knowledge, the zinc-MT biodistribution in PCa is not known. Hence, 
we performed IMS visualization of proteins in the m/z range of 0–20 kDa, where MTs are expected. Instead 
of a number of low-intensity peaks, the three major peaks were detected, where MT isoform 1X was identi-
fied. Disparities in MT1X expression reflected the administration type, and the lowest overall intensities were 
achieved in sar@LIP-administered tumors, consistent with our previous electrochemical analyses. Furthermore, 
the administration-related changes were found mostly in the marginal regions of tumors. One plausible expla-
nation is the enhanced angiogenesis of the margins, causing the accumulation of our designated nanotrans-
porters. Hence, the liposomal formulations act mostly in these regions, significantly affecting prostate tumor 
progression. Although additional work is necessary to understand the mechanistic basis of sarcosine-induced MT 
down-regulation, it is apparent that pathological changes in sarcosine metabolism leading to its accumulation in 
cells can be an important player in prostate tumorigenesis.
In conclusion, our exploratory study revealed that sarcosine plays an important role in PCa progression. 
Sarcosine administration significantly affected genes linked with proliferation and apoptosis, and thus, signif-
icantly stimulated in vivo tumor xenograft growth. Treatment with sar@LIP decreased the amounts of tumor 
zinc and MT. However, the mechanistic basis of the sarcosine influence on MT regulation needs to be further 
investigated. In contrast, using a liposomal formulation of our developed antisarAbs, we achieved mild antitumor 
activity, together with positive regulation of selected pro-apoptotic genes and elevations of tumor zinc and MT. 
Overall, sarcosine is an important oncometabolite affecting PCa progression. We have shown that sarcosine mol-
ecules are suitable targets for the development of biological treatment modalities. Although our antibodies exhib-
ited only moderate antitumor effects, further co-administration with various anticancer drugs should be tested 
to enhance the treatment efficiency. One option could be exploitation of specific inhibitors of enzymes involved 
in sarcosine biosynthesis, such as siRNA or aptamers. Song and coworkers have shown that siRNA knock-down 
of GNMT in PC-3 and LNCaP cells resulted in apparent decrease in proliferation with simultaneous increase 
of apoptotic cell counts42, however the knock-down effect on sarcosine amount was not investigated. Hence a 
question, whether the antiproliferative effects were due to a decrease in concentrations of intracellular sarcosine 
remains unanswered and further research is required to shed light into this phenomenon.
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Materials and Methods
Chemicals. All reagents for syntheses, standards, and other chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) in ACS purity, unless otherwise noted.
Liposome synthesis and sarcosine and antisarAbs encapsulation. Liposomes were prepared fol-
lowing the lipidic thin-film hydration method. Briefly, 100 mg of cholesterol, 100 mg of 1,2-dioleoyl-sn-glycero-3- 
phosphoethanolamine (DOPE) and 100 mg of phosphatidylcholine were dissolved in chloroform (4.5 mL). A 
lipidic film was obtained by rotary evaporation of solvent. The residual chloroform was blown out with nitrogen 
until a thin film was formed. For encapsulation, 500 μ L of sarcosine (200 μ g/mL) and antisarAbs (500 μ g/mL), 
produced in leghorn hens as described in our previous study11, was utilized. After addition to the lipidic film 
(10 mg), the samples were sonicated in an ultrasonic bath (15 min). The sample was then heated on a Biosan 
Thermo Shaker TS-100C (Biosan, Riga, Latvia) for 15 min at 60 °C. After cooling, FA was poured, followed by the 
addition of 1,1′ -carbonyldiimidazole (CDI) (the molar ratio of CDI to FA was 1:1). The samples were shaken on a 
thermoshaker for 2 h. Finally, the liposomes were filtered using Amicon® Ultra 0.5 mL centrifugal filters (Merck 
Millipore, Billerica, MA, USA) to remove unbound residual impurities.
Transmission electron microscopy (TEM). Liposomes were suspended within a drop of MilliQ purified 
H2O. The resulting suspension was covered with a grid-coated formvar film (Sigma-Aldrich) and carbon (Agar 
Scientific, Essex, UK). After drying, 2% ammonium molybdate was placed onto the grid, and the excess was dried. 
Liposomes were examined using a Philips 208 S Morgagni transmission electron microscope (FEI, Brno, Czech 
Republic) at 18,000× magnification and an accelerating voltage of 80 kV.
Determination of the mean hydrodynamic diameter of the liposomal transporter. The lipos-
ome hydrodynamic diameters were examined using a Particle Size Analyzer (Zetasizer Nano ZS90, Malvern 
Instruments, Malvern, UK). Particles were dispersed in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM 
KCl, 1.4 mM NaH2PO4, and 4.3 mM Na2HPO4, pH 7.4) and were incubated at 25 °C for 15 min before the 
measurement.
Optical characterization of liposomes. Absorbance and photoluminescence were examined using 
a Tecan Infinite 200 PRO multifunctional microplate reader (Tecan, Männedorf, Switzerland) in Costar® 
UV-transparent 96-well microplates with flat bottoms (Corning Inc., Corning, NY, USA). To determine the sur-
face modification, λ exc = 360 nm of FA was used.
Determination of loading efficiency in the liposomes. Loading efficiency (LE%) was determined by 
measuring the concentration of unencapsulated free sarcosine and antisarAbs in aqueous medium. For this pur-
pose, 400 μ L of liposomes was centrifuged (10,000 rpm, 15 min, 4 °C) in Amicon® Ultra 0.5 mL centrifugal filters 
(Merck Millipore), and the concentration of free sarcosine was quantified using ion-exchange chromatography 
according to Heger et al.6. The concentration of free antisarAbs was examined using the Bradford assay43. LE% 
was estimated with the following formula: (Cargototal − Cargosupernatant)/Cargototal × 100.
Cells. The PC-3 human cell line, established from a grade 4 androgen-independent prostatic adenocarcinoma, 
was purchased from the Health Protection Agency Culture Collection (Salisbury, UK). The cells were grown in 
Ham’s 12 medium with 7% fetal bovine serum (FBS) supplemented with penicillin (100 U/mL) and streptomycin 
(0.1 mg/mL). The PNT1A human cell line established by the immortalization of normal adult prostatic epithelial 
cells by transfection with a plasmid containing the SV40 genome with a defective replication origin was employed 
as a control model for microarray analyses (S1). The cells were cultured in RPMI-1640 medium with 10% FBS. 
The cells were maintained at 37 °C in a humidified incubator (Sanyo, Moriguchi, Japan) with 5% CO2.
Determination of intracellular uptake of antisarAbs@LIP. To determine the intracellular uptake, 
antisarAbs were fluorescently labeled with CdTe quantum dots (QDs) through a synthetic heptapeptide HWR 
linker prior to encapsulation, as described in our previously published studies11,44. PC-3 cells were seeded onto a 
plate at a density of 2.0 × 105 cells/well and were incubated for 24 h. Microscopy studies were performed using an 
Olympus IX 71S8F-3 inverted fluorescence microscope (Olympus, Tokyo, Japan) equipped with an HBO 50 W 
mercury arc lamp (Osram GmbH, Munich, Germany). The 545 and 580 nm excitation filters and the 610 nm 
emission filter were utilized. Images were acquired with an Olympus DP73 camera and processed using Stream 
Basic 1.7 software (Olympus) at a resolution of 1,600 × 1,200 pixels. To evaluate the competitive inhibitory effects 
of FA, various FA concentrations (final FA concentrations 2; 8 and 20 mM) were utilized for pre-treatment, fol-
lowed by subsequent treatment with 10 μ M QD-labeled antisarAbs@LIP and incubation for 4 h. The cells were 
then washed with medium, trypsinized and harvested. The median QD fluorescence values were analyzed using a 
Tecan Infinite 200 PRO multifunctional microplate reader (Tecan, Maennedorf, Switzerland) using λ ex = 500 nm 
and λ em = 610 nm.
Prostate tumor xenograft models. Five-week-old male nude athymic BALB/c nu/nu mice were used for 
xenograft studies. PC-3 cells (5 × 106) were resuspended in 100 μ L of PBS with 20% Matrigel (BD Biosciences, 
Franklin Lakes, NJ, USA) and were then implanted subcutaneously into the left flank regions of the mice under 
general anesthesia (1% Narkamon + 2% Rometar, 0.5 mL/100 g of weight). Growth in tumor volume was recorded 
using digital calipers, and tumor volumes were calculated using the formula: (π/6) × (L × W2), where L is the 
length of tumor and W is the width. The use of the animals followed the European Community Guidelines as 
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accepted principles for the use of experimental animals. The experiments were performed with the approval of the 
Ethics Commission at the Faculty of Medicine, Masaryk University, Brno, Czech Republic.
RNA isolation and reverse transcription. Tumors were crushed using a mortar and pestle under liquid 
nitrogen and were then mixed with 350 μ L of Tissue Lysis Buffer (Roche, Basel, Switzerland) in an Eppendorf tube. 
After 30 min incubation at 25 °C, samples were centrifuged (13,000 × g at 20 °C for 2 min) using an Eppendorf 
5402 microcentrifuge (Eppendorf, Hamburg, Germany). Next, 350 μ L of the lysate supernatant was pipetted into 
the sample tube, a component of the MagNA Pure Compact RNA Isolation Kit (Roche, Basel, Switzerland). The 
isolation steps were performed according to the manufacturer’s instructions. The concentration of the RNA was 
quantified using an Infinite M200 PRO (Tecan). The RNA was converted to cDNA using a PrimeScript One Step 
RT-PCR Kit (TaKaRa, Mountain View, CA, USA) with the following reaction profile: 25 °C for 10 min, 37 °C for 
120 min and 85 °C for 5 min. The cDNA integrity was tested by PCR of β-actin with the following primers: for-
ward 5′ -CCTGAACCCTAAGGCCAACC-3′ and reverse 5′ -GCAATGCCTGGGTACATGGT-3′ . The resulting 
DNA fragment (600 bp) was visualized using agarose gel electrophoresis with ethidium bromide staining as pre-
viously described by Nejdl et al.45.
Electrochemical microarray analyses. Obtained cDNA was biotinylated on its 3′ end using the Biotin 
3′ End DNA Labeling Kit (Thermo Scientific, Waltham, MA, USA) following the manufacturer’s instructions. 
The microarray was performed as previously described by Roth et al.46. For hybridization, Human Cancer 
3711 ElectraSense 4 × 2k array slides with 1,609 DNA probes (Custom Array, Bothell, WA, USA) were first 
pre-hybridized for 30 min at 50 °C using 6× SSPE (0.9 M NaCl, 60 mM sodium phosphate, 6 mM EDTA), 5× 
Denhardt’s solution and sonicated salmon sperm DNA (100 μ g/mL). Then, hybridization of biotin-labeled cDNA 
was performed at 50 °C for 18 h in 6× SSPE and salmon sperm DNA (100 μ g/mL). Array chips were rinsed with 
low ionic strength 3× SSPET (3× SSPE, 0.05% Tween-20) and PBST (2× phosphate-buffered saline, pH 7.4, 0.1% 
Tween-20) to remove weakly bound DNA. Subsequently, array chips were blocked with biotin blocking solution 
for 15 min. Chips were then incubated for 30 min with poly-horseradish peroxidase-streptavidin (1:1,000 in PBS 
containing 1% BSA and 0.05% Tween-20). Next, chips were rinsed three times with biotin wash solution and 3,3′ , 
5,5′ -tetramethylbenzidine (TMB) rinse solution, followed by incubation with TMB substrate. Measurements were 
performed using the ElectraSense detection kit (Custom Array). All post-hybridization processing steps were 
performed at 25 °C. The expression levels of selected genes were validated through qRT-PCR using SYBR® Green 
I Nucleic Acid Gel Stain (Invitrogen, Waltham, MA, USA) and the primers shown in Supplementary Table 1.
Western blot analysis. Tumor tissue for detection of caspase-3, cleaved caspase-3 and β -actin was pro-
cessed and analyzed according to previously published protocol47. In brief, after the lysis, 50 μ g of proteins were 
separated by 12% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After transfer onto poly-
vinylidene fluoride (PVDF) membranes and blocking with 5% (w/v) skim milk, the primary antibodies (Cell 
Signaling Technology, Danvers, MA, USA) were added overnight on the shaker at 4 °C. Then PVDF membranes 
were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at 25 °C. The detection was 
carried out using 3-aminoethyl-9-carbazole in 0.5 M acetate buffer as substrate.
Histological procedures. The samples were fixed in formaldehyde (10%) overnight, subsequently dehy-
drated in serial ethanol concentrations and embedded in paraffin wax. Sections were cut at 5 μ m, mounted on 
glass slides, deparaffinized and stained with hematoxylin-eosin. The microscopic observations were conducted 
using an Olympus IX 71S8F-3 (Olympus, Tokyo, Japan).
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) imaging mass spec-
trometry (IMS) and peptide mass fingerprinting (PMF). Sections of excised tumors (thickness 10 μ m) 
were mounted onto ITO glass slides (Bruker Daltonik, GmbH). Deparaffinization and antigen retrieval were 
performed according to Casadonte and Caprioli48. The glass slides were scanned with an Epson Perfection V500 
(Epson Europe, Amsterdam, Netherland) with a resolution of 2,400 DPI. Subsequently, 2,5-dihydroxybenzoic acid 
(DHB) (30 mg/mL in 50% methanol and 0.2% trifluoroacetic acid) was sprayed using an ImagePrep vibrational 
sprayer system (Bruker Daltonik, GmbH). The experiments were performed on a MALDI-TOF/TOF Bruker 
ultrafleXtreme (Bruker Daltonik, GmbH). The scanning raster was set to 100 μ m. Analyses were performed in 
reflectron positive mode with a laser power of 65%. The mass spectra were typically acquired in the m/z range 
0.5–20 kDa by averaging 1,600 sub spectra from a total of 1,600 laser shots per raster spot. After analyses, the 
mass spectra were automatically loaded into flexAnalysis and processed (baseline subtraction). Pseudo-colored 
images of spatial distribution were generated using GIMP 2.8 (http://www.gimp.org/). Identification of proteins 
was performed using PMF with in situ trypsin digestion. First, trypsin (0.05 μ g/μ L in water) was deposited to 
cover the entire tissue surface. Subsequently, DHB (30 mg/mL in 50% methanol and 0.2% trifluoroacetic acid) was 
deposited using a vibrational sprayer system (Bruker Daltonik, GmbH). Identification of trypsinized proteins was 
achieved with conventional algorithms using the MASCOT server (Matrix Science, Boston, MA, USA). The fol-
lowing parameters were used for database searches: trypsin was used as the enzyme, zero or one missed cleavage 
was allowed, taxonomy was set to Homo sapiens, oxidation of methionine or/and N-term acetylation were added 
as variable modifications, peptide tolerance was set to ± 0.5 Da, and mass values were set as MH+.
Preparation of tumor tissue to determine zinc content. Ten milligrams of tumor was digested in 
nitric acid (65% v/v) and hydrogen peroxide (30 v/v) at a ratio of 7:3 in a Microwave System 3000 (Anton Paar 
GmbH, Graz, Austria) using a MG-65 rotor. Microwave power was set to 100 W (30 min) at 140 °C.
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Atomic absorption spectrometry of zinc. Measurements were performed on a 280Z atomic absorption 
spectrometer (Agilent, Technologies, Santa Clara, CA, USA) with electrothermal atomization and Zeeman back-
ground correction. Zinc was measured on the primary wavelength Zn 213.9 nm (spectral bandwidth 0.5 nm, lamp 
current 10 mA) in the presence of a Pd chemical modifier.
Preparation of tumor tissue to determine total protein and MT amounts. Tumors were frozen 
with liquid nitrogen and homogenized using a SONOPLUS mini20 ultrasonic homogenizer (Bandelin Electronic, 
Berlin, Germany). Subsequently, 1 mL of 0.2 M phosphate buffer (pH, 7.0) was added, and the sample was 
homogenized for 5 min. The homogenates were further centrifuged using a Microcentrifuge 5417R (Eppendorf, 
Hamburg, Germany) at 15,000 × g, 4 °C for 15 min. Finally, the supernatant was filtered through a membrane 
filter (0.45 μ m nylon filter disk; Millipore, Billerica, MA, USA) and analyzed.
Determination of total protein content. The total protein concentrations were utilized for results nor-
malization and were quantified using a SKALAB CBT 600T kit (Skalab, Svitavy, Czech Republic) according to 
manufacturer instructions with a BS-400 automated spectrophotometer (Mindray, Schenzhen, China).
Determination of amount of total MTs. MT was quantified using differential pulse voltammetry (747 VA 
Stand, connected to a 693 VA processor and 695 Autosampler, Metrohm, Herissau, Switzerland) with the condi-
tions used in our previous study49.
Descriptive statistics. Results are expressed as the mean ± standard deviation unless noted otherwise. 
Differences between groups were analyzed using the paired t-test and analysis of variance (ANOVA). Unless 
noted otherwise, the threshold for significance was p < 0.05. Statistica 12 software (StatSoft, Tulsa, OK, USA) was 
employed for analyses.
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